Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at UnitedHealth (NYSEUNH) and its peers.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Progyny (NASDAQPGNY) and its peers.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 1.7%. This performance is a noticeable divergence from the S&P 500’s 8.9% return.
Walgreens Boots Alliance further reduced stake in Cencora. Walgreens reports early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares.
Cencora, Inc. (NYSECOR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.
Healthcare distributor Cencora (NYSECOR) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 12.8% year on year to $81.49 billion. Its non-GAAP profit of $3.73 per share was 6% above analysts’ consensus estimates.
Cencora posted Q1 sales of $81.5 billion, exceeding forecasts, with strong GLP-1 drug sales. Adjusted EPS beat estimates, and FY25 guidance was raised.
Cencora, Inc. (NYSECOR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.50 for the first quarter of fiscal 2025 compared to $2.98 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 13.7 percent to $3.73 in the fiscal first quarter from $3.28 in the prior year first quarter.
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.
Cencora, Inc. (NYSECOR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025.
Cencora, Inc. (NYSECOR) today announced the completion of its previously announced acquisition of Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists.
